Chairman Li Qiling increased his holdings of DAWNRAYS PHARMA (02348) by 52,000 shares at a price of HK$1.22 per share.
On November 3, Chairman Li Qiling increased his holdings in Dongrui Pharmaceutical (02348) by 52,000 shares, with a price of 1.22 Hong Kong dollars per share, for a total amount of approximately 63,400 Hong Kong dollars.
According to the latest data from the Hong Kong Stock Exchange, on November 3, Chairman Li Qiling increased his stake in DAWNRAYS PHARMA (02348) by 52,000 shares, with a price of 1.22 Hong Kong dollars per share, totaling approximately 63,400 Hong Kong dollars. After the increase, the latest number of shares held is approximately 711 million shares, with a latest shareholding ratio of 47.26%.
This transaction involves another related party: Xiong Rongli.
Related Articles
US Stock Market Move | AMD (AMD.US) fell more than 5%, and the cooperation between NVIDIA Corporation and Intel Corporation will intensify market competition.
MACAU LEGEND (01680) suggests canceling the share premium account and capital restructuring.
Cloud giants intensify competition in self-developed chip, Alphabet Inc. Class C (GOOG.US, GOOGL.US) Ironwood challenges NVIDIA Corporation's GPU dominance.
US Stock Market Move | AMD (AMD.US) fell more than 5%, and the cooperation between NVIDIA Corporation and Intel Corporation will intensify market competition.
MACAU LEGEND (01680) suggests canceling the share premium account and capital restructuring.
Cloud giants intensify competition in self-developed chip, Alphabet Inc. Class C (GOOG.US, GOOGL.US) Ironwood challenges NVIDIA Corporation's GPU dominance.
RECOMMEND
SERES Faces Market Test in Hong Kong: Shares Open Below Issue Price Despite HK$220 Billion Market Valuation
06/11/2025
Copper Prices Surge While Former “Copper King” Who Outpaced Huawei and Tencent Falls into Decline
06/11/2025
National Energy Administration Reports New-Type Energy Storage Capacity Exceeds 100 Million Kilowatts by End‑September
06/11/2025
